Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2005

View Archived Issues

CNS-5161 induces analgesic effects in patients with chronic neuropathic pain

Novel gene therapy for chronic pain targets glia / News in Context

Specific class II HDAC inhibitors for beta-thalassemia and sickle cell anemia treatment

KR-32570 improves functional and metabolic dysfunction post-ischemia

Neurocrine reviews pipeline progress

ISIS-301012 improves the lipid profile of patients with hypercholesterolemia

New data on the pharmacokinetics of dabigatran etexilate in humans

Acarbose shows promise in the treatment of renal disease

Phase II study under way with VX-702 for rheumatoid arthritis

Phase I study for Tarvacin in refractory advanced solid tumors

Cell Therapeutics sells Trisenox to Cephalon

Silodosin enters phase III in U.S. for BPH

Renovis ends phase Ia study of REN-850

FDA approves Adacel vaccine

Exelixis in transaction to fund development of drug candidates

Exelixis grants license to XL-119 to Helsinn Healthcare

U.S. Navy submits IND for Hemopure trauma trial

FDA agrees to rolling NDA for Virulizin

Non-approvable letter for Velac

AG-041R induces chondrogenesis via TGF-beta induction and MAPK activation

Dopamine D2 receptor ligands from Pfizer

Recent patents disclose novel treatments for HIV infection

New treatment options for respiratory and allergic disorders disclosed in recent patents

Low-dose PARP inhibitor combination therapy effective in early peripheral diabetic neuropathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...